Donate Today and Support Innovative Oncology Startups that Could Save Lives
AIM-HI seeks to pool public donations to support early stage oncology companies, assisting them to generate critical data for proof of concept and proof of value on the path to clinical trials, and, eventually, to new effective therapeutics and diagnostics that could save patients’ lives.
Donate to AIM-HI
If you own a Donor Advised fund, you may be able to donate from your fund directly to AIM-HI.
With the recent tax changes, more of our donors have been taking advantage of Donor Advised Funds (DAF). This DAF Direct service allows you to direct your donations to AIM-HI with a simple click of a button. DAF Direct currently facilitates grant recommendations from donors of Fidelity Charitable ®, Schwab Charitable ® and BNY Mellon Charitable Gift Fund ®. More national and community foundation DAF sponsoring organizations may be added in the future.
For more information, please contact 1-800-321-CURE (2873).
AIM-HI seeks to pool public donations to support early stage oncology companies. If you have securities purchased over a year ago with large amounts of unrealized capital gains in your taxable accounts, consider giving some to the AIM-HI Accelerator Fund from a tax planning perspective. Capital gains tax is not due on gain in the donated securities, and you will benefit from a charitable tax deduction equal to the value of such securities. Donate Today to help accelerate life-saving innovations!
Information for Electronic Stock Transfer to the AIM-HI Accelerator Fund
| Account# | WS87224 |
| DTC# | 0221 |
| Tax ID# | 82-4322538 |
| Broker Address | UBS | 1501 K. Street NW, Suite 1100, Washington, DC 20005 |
| Telephone | (202) 654-6601 | Guillermo Garcia |
Please contact us via mail, email, fax or telephone regarding the purpose of the gift when the transfer is made. If you have any questions, please contact Brian Wachtel at 301-654-1250. The fax number is 301-654-5824. Please send email to Info@AIM-HIAccelerator.org.
Thank you for your support of the AIM-HI Accelerator Fund!
Donate to Support Innovative T-cell Therapy Development
T-cells are the body’s defense against foreign invaders, and the mutations in tumor cells make them “foreign” to the body. The cancer, however, has developed ways to hide from T-cells. Unlike chemotherapy and radiation that “poison” cancer cells and normal cells alike, T-cells can be “educated” to recognize and find only tumor cells. So, they are potent AND specific, the ‘holy grail’ of cancer therapy.
Current T-cell therapy is effective, but expensive, need major hospitals, and require companion treatments that are toxic. For that reason, their likely use will be limited to when other treatments have failed.
The next generation of T-cell therapies being developed are inexpensive and non-toxic because they require no companion treatments. Once approved, they can be used in an outpatient clinic..
This next generation of T cell products is designed for first line therapy. For these reasons, AIM-HI is looking for support to help accelerate this approach of innovative T-Cell Therapies.
Together, we can make the next generation of cancer treatments a reality.